<div class="container">

<table style="width: 100%;"><tr>
<td>EFVfull</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Pharmacoepidemiological HIV treatment data
</h2>

<h3>Description</h3>

<p>A hypothetical, simulated dataset which is line with the data-generating process of Schomaker et al. (2023) and inspired by the data of Bienczak et al. (2017); see references below. Compared to the dataset <code>EFV</code>, it contains all variables of the DAG in Figure 3 of Schomaker et al. (2023), also those which are not needed for identification of the counterfactual quantity of interest; that is, the expected viral suppression (<code>VL</code>) under a specific intervention on efavirenz concentrations (<code>efv.0, efv.1, ...</code>).
</p>


<h3>Usage</h3>

<pre><code class="language-R">data(EFVfull)</code></pre>


<h3>Format</h3>

<p>A data frame with 5000 observations on the following variables:
</p>

<dl>
<dt><code>sex</code></dt>
<dd>
<p>The patient's sex</p>
</dd>
<dt><code>metabolic</code></dt>
<dd>
<p>Metabolism status (slow, intermediate, extensive) related to the single nucleotide polymorphisms in the CYP2B6 gene, which is relevant
for metabolizing evafirenz and directly affects its concentration in the body.</p>
</dd>
<dt><code>log_age</code></dt>
<dd>
<p>log(age) at baseline</p>
</dd>
<dt><code>NRTI</code></dt>
<dd>
<p>Nucleoside reverse transcriptase inhibitor (NRTI) component of HIV treatment, i.e.
abacavir, stavudine or zidovudine.</p>
</dd>
<dt><code>weight.0</code></dt>
<dd>
<p>log(weight) at time 0 (baseline)</p>
</dd>
<dt><code>comorbidity.0</code></dt>
<dd>
<p>Presence of co-morbidities at time 0 (baseline)</p>
</dd>
<dt><code>dose.0</code></dt>
<dd>
<p>Dose of efavirenz administered at time 0 (basline)</p>
</dd>
<dt><code>efv.0</code></dt>
<dd>
<p>Efavirenz concentration at time 0 (baseline)</p>
</dd>
<dt><code>VL.0</code></dt>
<dd>
<p>Elevated viral load (viral failure) at time 0 (baseline)</p>
</dd>
<dt><code>adherence.1</code></dt>
<dd>
<p>Adherence at time 1 (if 0, then signs of non-adherence)</p>
</dd>
<dt><code>weight.1</code></dt>
<dd>
<p>log(weight) at time 1</p>
</dd>
<dt><code>comorbidity.1</code></dt>
<dd>
<p>Presence of co-morbidities at time 1</p>
</dd>
<dt><code>dose.1</code></dt>
<dd>
<p>Dose of efavirenz administered at time 1</p>
</dd>
<dt><code>efv.1</code></dt>
<dd>
<p>Efavirenz concentration at time 1</p>
</dd>
<dt><code>VL.1</code></dt>
<dd>
<p>Elevated viral load (viral failure) at time 1</p>
</dd>
<dt><code>adherence.2</code></dt>
<dd>
<p>Adherence at time 2 (if 0, then signs of non-adherence)</p>
</dd>
<dt><code>weight.2</code></dt>
<dd>
<p>log(weight) at time 2</p>
</dd>
<dt><code>comorbidity.2</code></dt>
<dd>
<p>Presence of co-morbidities at time 2</p>
</dd>
<dt><code>dose.2</code></dt>
<dd>
<p>Dose of efavirenz administered at time 2</p>
</dd>
<dt><code>efv.2</code></dt>
<dd>
<p>Efavirenz concentration at time 2</p>
</dd>
<dt><code>VL.2</code></dt>
<dd>
<p>Elevated viral load (viral failure) at time 2</p>
</dd>
<dt><code>adherence.3</code></dt>
<dd>
<p>Adherence at time 3 (if 0, then signs of non-adherence)</p>
</dd>
<dt><code>weight.3</code></dt>
<dd>
<p>log(weight) at time 3</p>
</dd>
<dt><code>comorbidity.3</code></dt>
<dd>
<p>Presence of co-morbidities at time 3</p>
</dd>
<dt><code>dose.3</code></dt>
<dd>
<p>Dose of efavirenz administered at time 3</p>
</dd>
<dt><code>efv.3</code></dt>
<dd>
<p>Efavirenz concentration at time 3</p>
</dd>
<dt><code>VL.3</code></dt>
<dd>
<p>Elevated viral load (viral failure) at time 3</p>
</dd>
<dt><code>adherence.4</code></dt>
<dd>
<p>Adherence at time 4 (if 0, then signs of non-adherence)</p>
</dd>
<dt><code>weight.4</code></dt>
<dd>
<p>log(weight) at time 4</p>
</dd>
<dt><code>comorbidity.4</code></dt>
<dd>
<p>Presence of co-morbidities at time 4</p>
</dd>
<dt><code>dose.4</code></dt>
<dd>
<p>Dose of efavirenz administered at time 4</p>
</dd>
<dt><code>efv.4</code></dt>
<dd>
<p>Efavirenz concentration at time 4</p>
</dd>
<dt><code>VL.4</code></dt>
<dd>
<p>Elevated viral load (viral failure) at time</p>
</dd>
</dl>
<h3>References</h3>

<p>Schomaker M, McIlleron H, Denti P, Diaz I. (2023) <em>Causal Inference for Continuous Multiple Time Point Interventions</em>, ArXiv e-prints: <em>https://arxiv.org/abs/2305.06645</em>.
</p>
<p>Bienczak et al. (2017) <em>Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets</em>, AIDS, <em>31:905-915</em>
</p>


<h3>Examples</h3>

<pre><code class="language-R">data(EFVfull)
str(EFVfull)
</code></pre>


</div>